United Therapeutics Corporation Company Profile (NASDAQ:UTHR)

United Therapeutics Corporation trades on the NASDAQ under the ticker symbol "UTHR."

United Therapeutics Corporation announced that its board has authorized a share buyback plan on Sunday, June 4th 2017, which allows the company to repurchase $250,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization allows the company to purchase up to 4.6% of its stock through open market purchases. Stock repurchase plans are usually an indication that the company's board of directors believes its shares are undervalued.

United Therapeutics Corporation (NASDAQ:UTHR) announced its earnings results on Thursday, July, 27th. The company reported ($1.25) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of $3.61 by $4.86. The company had revenue of $444.60 million for the quarter, compared to analysts' expectations of $391.53 million. United Therapeutics Corporation had a return on equity of 20.96% and a net margin of 24.18%. United Therapeutics Corporation's quarterly revenue was up 7.8% on a year-over-year basis. During the same quarter in the prior year, the business earned $4.42 earnings per share. View United Therapeutics Corporation's Earnings History.

United Therapeutics Corporation is scheduled to release their next quarterly earnings announcement on Thursday, October, 26th 2017. View Earnings Estimates for United Therapeutics Corporation.

11 analysts have issued twelve-month price objectives for United Therapeutics Corporation's stock. Their predictions range from $95.00 to $213.00. On average, they expect United Therapeutics Corporation's share price to reach $134.70 in the next twelve months. View Analyst Ratings for United Therapeutics Corporation.

Here are some recent quotes from research analysts about United Therapeutics Corporation stock:

• 1. According to Zacks Investment Research, "United Therapeutics holds a strong position in the pulmonary arterial hypertension (PAH) market with four approved products targeting this indication. The company is working on new delivery mechanisms for Remodulin and expanded indications for its other marketed products like Orenitram and Tyvaso to drive long-term growth. However, competition in the PAH market is on the rise. Lately, the growth of its PAH drugs Orenitram, Tyvaso and Remodulin have slowed due to competition from Uptravi and Adcirca + Letairis combination therapy. Recently, United Therapeutics announced that regulatory issues will delay the U.S. launch of RemoSynch. Adcirca is also expected to lose patent exclusivity in Nov 2017. United Therapeutics’ shares underperformed the drugs industry this year so far. Estimates have remained stable ahead of the Q2 earnings release. The company has a record of positive earnings surprises in the recent quarters." (7/13/2017)
• 2. Cowen and Company analysts commented, "1Q Revenues were weak across the prostacyclin PAH franchise." (4/26/2017)
• 3. Credit Suisse Group analysts commented, "The recent acquisition of UTHR's competitor has driven a large M&A premium in UTHR shares, and we see downside due to potential near-term and generic risk starting late 2017-2018. United Therapeutics' product franchise consists of pulmonary arterial hypertension (PAH) therapies. PAH is essentially high blood pressure in the lungs. We think an acquisition for United Therapeutics is unlikely in the near term since the company has mentioned doing deals to acquire. We see catalysts in the coming month that could lead to downside in shares, especially with shares trading above (~20%), the level at which we see the fundamental value of the company. In the long term, we remain more cautious on what the current valuation would suggest around risk to UTHR's PAH franchise from generics launching as early as 2018. We think that the stock trades at a higher non-GAAP P/E multiple than what consensus actually shows; we estimate 2018 and 2019 P/E multiples of 15x and 20x vs. consensus of 10x and 11x, respectively." (3/16/2017)
• 4. Jefferies Group LLC analysts commented, "Our physician poll indicates continuing competitor Uptravi impact on UTHR's treprostinil franchise & meaningful headwinds from generic Remodulin - potentially ~35% of current sales at risk. Yet, current consensus est's do not reflect such downside risks, particularly a potential real threat from generic Remodulin in 2018. Downgrading UTHR to Underperform from Hold, but keeping $116 PT." (3/6/2017)
• 5. Wedbush analysts commented, "With consistent YoY growth in revenues, free cash flow and a deep pipeline of diverse assets in late-stage development, we continue to believe UTHR continues to be an attractive long-term investment. ' Q4 and 2016 top and bottom line missed on seasonal choppiness and transient warehousing of Remodulin and Tyvaso patients. Reported Q4/FY:16 revenues of $409MM/$1599MM came in below consensus estimates of $416MM/$1605MM. GAAP EPS of $2.43/$15.25 also missed consensus estimates of $3.68/$16.46. While Remodulin and Adcirca beat, Tyvaso and Orenitram missed. Management indicated their view that patient warehousing with oral PAH medications is transient and anticipates sales acceleration for Tyvaso and Remodulin later in 2017 as the effect of oral PAH medications begins to wane and PAH patients need a new medication. UTHR ended 2016 with ~$1.053BN in cash & cash eq. Management implied that instead of pursing another share buyback, they may announce business development activities." (2/27/2017)

Some companies that are related to United Therapeutics Corporation include Alkermes PLC (ALKS), Seattle Genetics (SGEN), Ionis Pharmaceuticals (IONS), Qiagen N.V. (QGEN), Alnylam Pharmaceuticals (ALNY), Icon Plc (ICLR), INC Research Holdings (INCR), Galapagos NV (GLPG), Exact Sciences Corporation (EXAS), Charles River Laboratories International (CRL), PRA Health Sciences (PRAH), Bio-Techne Corp (TECH), PAREXEL International Corporation (PRXL), ACADIA Pharmaceuticals (ACAD), FibroGen (FGEN), Puma Biotechnology (PBYI), Nektar Therapeutics (NKTR) and WuXi PharmaTech (Cayman) (WX).

United Therapeutics Corporation's management team includes the folowing people:

• Martine A. Rothblatt Ph.D. J.D., Chairman of the Board, Chief Executive Officer
• Michael Benkowitz, President, Chief Operating Officer
• Christopher Patusky J.D., Lead Independent Vice Chairman of the Board
• James C. Edgemond, Chief Financial Officer, Treasurer
• Paul A. Mahon J.D., Executive Vice President, General Counsel, Corporate Secretary
• Raymond A. Dwek, Non-Independent Director
• Christopher Causey, Independent Director
• Richard A. Giltner, Independent Director
• Katherine J. Klein Ph.D., Independent Director
• Raymond C. Kurzweil J.D., Independent Director

United Therapeutics Corporation's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (11.27%), FMR LLC (9.79%), Vanguard Group Inc. (8.77%), State Street Corp (4.64%), Palo Alto Investors LLC (4.30%) and Acadian Asset Management LLC (2.53%). Company insiders that own United Therapeutics Corporation stock include Christopher Causey, Christopher Patusky, Martine A Rothblatt, Paul A Mahon, Raymond Dwek, Richard Giltner and Tommy G Thompson. View Institutional Ownership Trends for United Therapeutics Corporation.

United Therapeutics Corporation's stock was sold by a variety of institutional investors in the last quarter, including AJO LP, LSV Asset Management, Los Angeles Capital Management & Equity Research Inc., WINTON GROUP Ltd, TIAA CREF Investment Management LLC, Old Mutual Global Investors UK Ltd., Westpac Banking Corp and Cornerstone Capital Management Holdings LLC.. Company insiders that have sold United Therapeutics Corporation stock in the last year include Christopher Causey, Christopher Patusky, Martine A Rothblatt, Raymond Dwek, Richard Giltner and Tommy G Thompson. View Insider Buying and Selling for United Therapeutics Corporation.

United Therapeutics Corporation's stock was acquired by a variety of institutional investors in the last quarter, including Wells Fargo & Company MN, JPMorgan Chase & Co., Renaissance Technologies LLC, Schroder Investment Management Group, Dimensional Fund Advisors LP, Prudential Financial Inc., BlackRock Inc. and FMR LLC. View Insider Buying and Selling for United Therapeutics Corporation.

Shares of United Therapeutics Corporation can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of United Therapeutics Corporation stock can currently be purchased for approximately $117.57.